Mochammad Fitri Atho’i̇llah
Yunita Diyah Safi̇tri̇
Farida Dewi Nur’ai̇ni̇
Sri Wi̇dyarti̇
Tsuboi Hi̇deo
Muhaimin Rifa’i

Abstract

Introduction:

The relationship between B cells and Toll-like Receptors (TLRs) under high fat−high fructose diet (HFFD) is still poorly understood. Isoflavone content from soybean can be modified by using biotic and abiotic elicitors to synthesize glyceollin. Glyceollin has gained much interest in recent past year due to its beneficial effects on health. The study aimed to examine the ameliorative effect of elicited soybean extract (ESE) on B cells profile in HFFD mice.

Material and Methods:

Twenty-eight female Balb/C mice were divided into normal diet (ND), ND + ESE 104 mg/kg, HFFD, HFFD + Simvastatin 2.8 mg/kg, ESE 78 mg/kg, 104 mg/kg, and 130 mg/kg, respectively. Mice were fed with HFFD for 24 weeks and ESE was administered orally per day at last 4 weeks. At week 24, the animals were sacrificed and the spleen was collected. B cells were labeled as B220+TLR3+, B220+TLR4+, B220+NFκB-, and B220+NFκB+ and the B cells expression were measured by flow cytometry. Molecular modeling was performed by Pyrx 0.8 and visualized in PyMol.

Results:

The ESE treatment significantly decreased B220+TLR3+, B220+TLR4+, and B220+NFκB+ expression and restored B220+NFκB− expression in HFFD mice (p<0.05). Glyceollin I exerted the lowest binding affinity with estimated energy was -7.0 kcal/mol at NFκB.

Conclusions:

ESE administration ameliorates HFFD-induced inflammation by modulating TLR3/TLR4 activation and prevents NFκB expression of B cells in HFFD mice. ESE exerts as a promising agent in the future and provides a better understanding mechanism to treat chronic inflammation caused by HFFD.

Keywords:

B cell, soybean, high fat-high fructose diet, NFu03baB, TLR3/TLR4

VOLUME

6

,

ISSUE

3
December 2018

Correspondence

Muhaimin Rifa’i

Email

immunobiology@ub.ac.id

Received

Accepted

Published

Suggested Citation

DOI

License

This work is licensed under the Creative Commons Attribution-NonCommercial-Non-Derivatives 4.0 International License (CC BY-NC-ND 4.0). License